Corpus overview


Overview

MeSH Disease

Human Phenotype

Fever (93)

Cough (57)

Pneumonia (27)

Dyspnea (18)

Fatigue (18)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 93
    records per page




    Symptom based and transmission TRANS-prevention based testing in long-term care facilities: Symptomatology, clinical course and mortality for residents with COVID-19

    Authors: Kelly C. Paap; Anouk M. van Loon; Sarian M. van Rijs; Esther Helmich; Bianca M. Buurman; Martin Smalbrugge; Cees M. P. M. Hertogh; Jinal Bhiman; Mushal Allam; Arshad Ismail; Susan Engelbrecht; Gert Van Zyl; Wolfgang Preiser; Carolyn Williamson; Francesco Pettruccione; Alex Sigal; Inbal Gazy; Diana Hardie; Marvin Hsiao; Darren Martin; Denis York; Dominique Goedhals; Emmanuel James San; Marta Giovanetti; Jose Lourenco; Luiz Carlos Junior Alcantara; Tulio de Oliveira

    doi:10.1101/2020.10.28.20221275 Date: 2020-10-30 Source: medRxiv

    Objectives: Initially, for preventing COVID-19 transmission TRANS in long-term care facilities (LTCF) primarily rely on presence of core symptoms ( fever HP fever MESHD, cough HP cough MESHD, dyspnea HP dyspnea MESHD), but LTCF residents may also show an atypical course of a SARS-CoV-2 infection MESHD. We described the clinical presentation and course of COVID-19 in LTCF residents who were tested either because of presence of core symptoms (S-based) or because of transmission TRANS prevention (TP-based) Design: Retrospective cohort study. Setting and participants: Amsta (Amsterdam, The Netherlands), is a 1185-bed LTCF. All LTCF residents who underwent SARS-CoV-2 RT-PCR testing between March 16, 2020 and May 31, 2020 were included (n = 380). Measures: Clinical symptoms, temperature and oxygen saturation were extracted from medical records, 7 days before testing up to 14 days after testing. Results: SARS-CoV-2 was confirmed in 81 (21%) residents. Of these 81, 36 (44%) residents were tested S-based and 45 (56%) residents were tested TP-based. Yet, CT-values did not differ between the groups. In the 7 days prior to the test the most common symptoms in both groups were: falling HP (32%), somnolence MESHD (25%) and fatigue HP fatigue MESHD (21%). Two days before the test, we observed a stronger decrease in oxygen saturation and an increase in temperature for the S-based group compared to the T-based group that remained up to 10 days after testing. Residents with in the S-based group were 2.5 times more likely to decease within 30 days than residents in the TP-based group (HR, 2.56; 95% 1.3 to 5.2). Even though, 73% of the T-based group did eventually developed core symptoms. Conclusion and implications: Many LTCF residents with a positive PCR did not have core symptoms when tested but had other signs/symptoms in the week before the positive test. Testing policies should therefore be adjusted to prevent transmission TRANS. Daily measures of temperature and oxygen saturation can contribute to earlier detection.

    Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial

    Authors: Patricia Rieken Macedo Rocco; Pedro Leme Silva; Fernanda Ferreira Cruz; Marco Antonio C.M. Junior; Paulo Fernando Guimaraes Morando Marzocchi Tierno; Marcos de Assis Moura; Luis Frederico Gerbase De Oliveira; Cristiano Cleidson Lima; Ezequiel Aparecido Dos Santos; Walter Freitas Junior; Ana Paula Salles Moura Fernandes; Kleber Gomes Franchini; Erick Magri; Nara Franzin de Moraes; Jose Mario de Jesus Goncalves; Melanie Nogueira Carbonieri; Ivonise Sampaio Dos Santos; Natalia de Fatima Paes; Paula Veronica Martini Maciel; Raissa Prado Rocha; Alex Fiorini de Carvalho; Pedro Augusto Alves; Jose Luiz Proenca Modena; Artur Torres Cordeiro; Daniela Barreto Barbose Trivella; Rafael Elias Marques; Ronir R Luiz; Paolo Pelosi; Jose Roberto Lapa e Silva

    doi:10.1101/2020.10.21.20217208 Date: 2020-10-23 Source: medRxiv

    The antiparasitic drug nitazoxanide is widely available and exerts broad-spectrum antiviral activity in vitro. However, there is no evidence of its impact on SARS-CoV-2 infection MESHD. In a multicenter, randomized, double-blind, placebo-controlled trial, adult TRANS patients who presented up to 3 days after onset of Covid-19 symptoms ( dry cough MESHD cough HP, fever HP fever MESHD, and/or fatigue HP fatigue MESHD) were enrolled. After confirmation of SARS-CoV2 infection MESHD by RT-PCR on nasopharyngeal swab, patients were randomized 1:1 to receive either nitazoxanide (500 mg) or placebo, TID, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, general laboratory tests, serum SERO biomarkers of inflammation MESHD, and hospitalization rate. Adverse events were also assessed. From June 8 to August 20, 2020, 1,575 patients were screened. Of these, 392 (198 placebo, 194 nitazoxanide) were analyzed. Median time from symptom onset TRANS to first dose of study drug was 5 (4-5) days. At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms. However, at the 1-week follow-up, 78% in the nitazoxanide arm and 57% in the placebo arm reported complete resolution of symptoms (p=0.048). Swabs collected were negative for SARS-CoV-2 in 29.9% of patients in the nitazoxanide arm versus 18.2% in the placebo arm (p=0.009). Viral load was also reduced after nitazoxanide compared to placebo (p=0.006). No serious adverse events were observed. In patients with mild Covid-19, symptom resolution did not differ between the nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.

    Clinical characteristics of 4490 COVID-19 patients in Africa: A meta-analysis

    Authors: Testimony Jesupamilerin Olumade; Leonard Ighodalo Uzairue; Takanao Tanaka; Tejal Vaghela; Matthew Knight; Rahul Moghal; Jaswinder Singh; Lisa G Spencer; Erica Thwaite; Harry Mitchell; Sam Calmonson; Noor Mahdi; Shershah Assadullah; Matthew Leung; Aisling O'Neill; Chhaya Popat; Radhika Kumar; Thomas J Humphries; Rebecca Talbutt; Sarika Raghunath; Philip L Molyneaux; Miriam Schechter; Jeremy Lowe; Andrew Barlow

    doi:10.1101/2020.10.20.20215905 Date: 2020-10-21 Source: medRxiv

    IntroductionThe novel coronavirus disease-2019 (COVID-19) pandemic that started in December 2019 has affected over 39 million people and killed over 1.1 million people. While more studies are published to help us understand the virus, there is a dearth of studies on the clinical characteristics and associated outcomes of the Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS-CoV-2) on the African continent. MethodsWe evaluated evidence from previous studies in Africa available in six databases between January 1 and October 6, 2020. Meta-analysis was then performed using Open-Meta Analyst software. ResultsA total of seven studies including 4490 COVID-19 patients were included. The result of the meta-analysis showed 68.8% of infected patients were male TRANS. Common symptoms presented (with their incidences) were fever HP (42.8%), cough HP (33.3%), headache HP (11.3%), breathing problems (16.8%). Other minor occurring symptoms included diarrhea HP (7.5%), and rhinorrhea HP (9.4%). Fatality rate was 5.6%. ConclusionThis study presents the first description and analysis of the clinical characteristics of COVID-19 patients in Africa. The most common symptoms are fever HP, cough HP and breathing problems.

    Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit

    Authors: Ayham Daher; Paul Balfanz; Maria Aetou; Bojan Hartmann; Dirk Müller-Wieland; Tobias Müller; Nikolaus Marx; Michael Dreher; Christian G Cornelissen

    doi:10.21203/rs.3.rs-95432/v1 Date: 2020-10-20 Source: ResearchSquare

    Purpose: Patients suffering from CVOID-19 mostly experience a benign course of the disease. Approximately 14 % of SARS-CoV2 infected MESHD patients are admitted to a hospital. Cohorts exhibiting severe lung failure MESHD in the form of acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) have been well characterized. Patients without ARDS MESHD but in need of supplementary oxygen have received much less attention. This study describes the diagnosis, symptoms, treatment and outcomes of hospitalized patients with COVID-19 needing oxygen support during their stay on regular ward.Methods: All 133 patients admitted to the RWTH Aachen university hospital with the diagnosis of COVID-19 were included in an observational registry. Clinical data sets were extracted from the hospital information system. This analysis includes all 57 patients requiring supplemental oxygen not admitted to the ICU.Results: 57 patients needing supplemental oxygen and being treated outside the ICU were analyzed. Patients exhibited the typical set of symptoms for COVID-19. Of note, hypoxic MESHD patients mostly did not suffer from clinically relevant dyspnea HP dyspnea MESHD despite oxygen saturations below 92 %. Patients had fever HP fever MESHD for 7 [2-11] days and needed supplemental oxygen for 8 [5-13] days resulting in an overall hospitalization time of 12 [7-20] days. In addition, patients had persisting systemic inflammation MESHD with CRP levels remaining elevated until discharge or death MESHD.Conclusion: This description of COVID-19 patients requiring oxygen therapy should be taken into account when planning treatment capacity. Patients on oxygen need long-term inpatient care.

    Antibody SERO-dependent enhancement (ADE) of SARS-CoV-2 infection MESHD in recovered COVID-19 patients: studies based on cellular and structural biology analysis

    Authors: Fan Wu; Renhong Yan; Mei Liu; Zezhong Liu; Yingdan Wang; Die Luan; Kaiyue Wu; Zhigang Song; Tingting Sun; Yunping Ma; Yuanyuan Zhang; Qimin Wang; Xiang Li; Ping Ji; Yaning Li; Cheng Li; Yanling Wu; Tianlei Ying; Yumei Wen; Shibo Jiang; Tongyu Zhu; Lu Lu; Yongzheng Zhang; Qiang Zhou; Jinghe Huang; Auke C Reidinga; Daisy Rusch; Kim CE Sigaloff; Renee A Douma; Lianne de Haan; Egill A Fridgeirsson; Niels C Gritters van de Oever; Roger JMW Rennenberg; Guido van Wingen; Marcel JH Aries; Martijn Beudel; ítalo Karmann Aventurato; Mariana Rabelo de Brito; Marina Koutsodontis Machado Alvim; José Roberto da Silva Junior; Lívia Liviane Damião; Maria Ercilia de Paula Castilho Stefano; Iêda Maria Pereira de Sousa; Elessandra Dias da Rocha; Solange Maria Gonçalves; Luiz Henrique Lopes da Silva; Vanessa Bettini; Brunno Machado de Campos; Guilherme Ludwig; Rosa Maria Mendes Viana; Ronaldo Martins; Andre S. Vieira; José Carlos Alves-Filho; Eurico de Arruda Neto; Adriano Sebollela; Fernando Cendes; Fernando Q Cunha Sr.; André Damásio; Marco Aurélio Ramirez Vinolo; Carolina Demarchi Munhoz; Stevens K Rehen Sr.; Thais Mauad; Amaro Nunes Duarte-Neto; Luiz Fernando Ferraz da Silva; Marisa Dolhnikoff; Paulo Saldiva; Alexandre Todorovic Fabro; Alessandro S Farias; Pedro Manoel M. Moraes-Vieira; José Luiz Proença Módena; Clarissa Lin Yasuda; Marcelo A. Mori; Thiago Mattar Cunha; Daniel Martins-de-Souza

    doi:10.1101/2020.10.08.20209114 Date: 2020-10-13 Source: medRxiv

    Antibody SERO-dependent enhancement (ADE) has been reported in several virus infections including dengue fever HP fever MESHD virus, severe acute respiratory syndrome MESHD (SARS) and Middle East respiratory syndrome (MERS) coronavirus infection MESHD. To study whether ADE is involved in COVID-19 infections, in vitro pseudotyped SARS-CoV-2 entry into Raji cells, K562 cells, and primary B cells mediated by plasma SERO from recovered COVID-19 patients were employed as models. The enhancement of SARS-CoV-2 entry into cells was more commonly detected in plasma SERO from severely-affected elderly TRANS patients with high titers of SARS-CoV-2 spike protein-specific antibodies SERO. Cellular entry was mediated via the engagement of Fc{gamma}RII receptor through virus-cell membrane fusion, but not by endocytosis. Peptide array scanning analyses showed that antibodies SERO which promote SARS-CoV-2 infection MESHD targeted the variable regions of the RBD domain. To further characterize the association between the spike-specific antibody SERO and ADE, an RBD-specific monoclonal antibody SERO (7F3) was isolated from a recovered patient, which potently inhibited SARS-Cov-2 infection of ACE-2 expressing cells and also mediated ADE in Raji cells. Site-directed mutagenesis the spike RBD domain reduced the neutralization activity of 7F3, but did not abolish its binding to the RBD domain. Structural analysis using cryo-electron microscopy (Cryo-EM) revealed that 7F3 binds to spike proteins at a shift-angled pattern with one up and two down RBDs, resulting in partial overlapping with the receptor binding motif (RBM), while a neutralizing monoclonal antibody SERO that lacked ADE activity binds to spike proteins with three up RBDs, resulting in complete overlapping with RBM. Our results revealed that ADE mediated by SARS-CoV-2 spike-specific antibodies SERO could result from binding to the receptor in slightly different pattern from antibodies SERO mediating neutralizations. Studies on ADE using antibodies SERO from recovered patients via cell biology and structural biology technology could be of use for developing novel therapeutic and preventive measures for control of COVID-19 infection MESHD.

    Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2 SERO after COVID-19

    Authors: Jim Boonyaratanakornkit; Chihiro Morishima; Stacy Selke; Danniel Zamora; Sarah McGuffin; Adrienne E Shapiro; Victoria L Campbell; Christopher L McClurkan; Lichen Jing; Robin Gross; Janie Liang; Elena Postnikova; Steven Mazur; Anu Chaudhary; Marie K Das; Susan L Fink; Andrew Bryan; Alex L Greninger; Keith R Jerome; Michael R Holbrook; Terry B Gernsheimer; Mark H Wener; Anna Wald; David M Koelle

    doi:10.1101/2020.10.06.20207472 Date: 2020-10-08 Source: medRxiv

    Background: SARS-CoV-2-specific antibodies SERO may protect from reinfection and disease, providing the rationale for administration of plasma SERO containing SARS-CoV-2 neutralizing antibodies SERO (nAb) as a treatment for COVID-19. The clinical factors and laboratory assays to streamline plasma SERO donor selection, and the durability of nAb responses, are incompletely understood. Methods: Adults TRANS with virologically-documented SARS-CoV-2 infection MESHD in a convalescent plasma SERO donor screening program were tested for serum SERO IgG to SARS-CoV-2 spike protein S1 domain, nucleoprotein (NP), and for nAb. Results: Amongst 250 consecutive persons studied a median of 67 days since symptom onset TRANS, 243/250 (97%) were seropositive on one or more assays. Sixty percent of donors had nAb titers [≥]1:80. Correlates of higher nAb titer included older age TRANS (adjusted OR [AOR] 1.03/year of age TRANS, 95% CI 1.00-1.06), male TRANS sex (AOR 2.08, 95% CI 1.13-3.82), fever HP fever MESHD during acute illness MESHD (AOR 2.73, 95% CI 1.25-5.97), and disease severity represented by hospitalization (AOR 6.59, 95% CI 1.32-32.96). Receiver operating characteristic (ROC) analyses of anti-S1 and anti-NP antibody SERO results yielded cutoffs that corresponded well with nAb titers, with the anti-S1 assay being slightly more predictive. NAb titers declined in 37 of 41 paired specimens collected a median of 98 days (range, 77-120) apart (P<0.001). Seven individuals (2.8%) were persistently seronegative and lacked T cell responses. Conclusions: Nab titers correlated with COVID-19 severity, age TRANS, and sex. Standard commercially available SARS-CoV-2 IgG results can serve as useful surrogates for nAb testing. Functional nAb levels were found to decline and a small proportion of COVID-19 survivors lack adaptive immune responses.

    A case report of greater saphenous vein thrombosis MESHD in a patient with coronavirus (COVID-19) infection MESHD

    Authors: Negin Hesam-Shariati; Poya Fatehi; Fardin Fathi; Morteza Abouzaripour; Mohamad Bakhtiar Hesam Shariati

    doi:10.21203/rs.3.rs-86688/v1 Date: 2020-10-01 Source: ResearchSquare

    In December 2019, the World Health Organization (WHO) announced a series of pneumonia HP pneumonia MESHD cases caused by an unknown origin, discovered in Wuhan, China. A dangerous virus called SARS-Cov-2 (severe acute respiratory syndrome coronavirus 2 MESHD) caused a disease named acute respiratory syndrome MESHD, which was later popularly called coronavirus infection MESHD (COVID-19). Patients with acute COVID-19 are at high risk for thrombosis MESHD in various blood SERO vessels due to over-coagulation, blood SERO stasis, and endothelial damage. To date, very little research has been done on the number and side effects of thromboembolic disorders MESHD in patients with COVID-19. In this study, we report a case with COVID-19, who was hospitalized in one of the hospitals in Sanandaj, Iran. There were symptoms of fever HP fever MESHD, chills HP, muscle aches MESHD, cough HP, and tachycardia HP tachycardia MESHD. Laboratory tests such as CRP, ESR, Ferritin CLIA, LDH and D-Dimer were observed in this patient at a high level. Doppler ultrasound of this patient revealed an abnormal finding, thrombosis MESHD in the right greater saphenous vein. This suggests that COVID-19 may lead to other side effects through damage to blood SERO vessels.

    Ruling In and Ruling Out COVID-19: Computing SARS-CoV-2 Infection Risk TRANS Infection Risk TRANS From Symptoms, Imaging and Test Data.

    Authors: Chistopher D'Ambrosia; Henrik Christensen; Eliah Aronoff-Spencer

    doi:10.1101/2020.09.18.20197582 Date: 2020-09-22 Source: medRxiv

    Background: Assigning meaningful probabilities of SARS CoV2 infection risk TRANS infection risk TRANS presents a diagnostic challenge across the continuum of care. Methods: We integrated patient symptom and test data using machine learning and Bayesian inference to quantify individual patient risk of SARS CoV 2 infection MESHD. We trained models with 100,000 simulated patient profiles based on thirteen symptoms, estimated local prevalence SERO, imaging, and molecular diagnostic performance SERO from published reports. We tested these models with consecutive patients who presented with a COVID 19 compatible illness at the University of California San Diego Medical Center over 14 days starting in March 2020. Results: We included 55 consecutive patients with fever HP fever MESHD (78%) or cough HP cough MESHD (77%) presenting for ambulatory (n=11) or hospital care (n=44). 51% (n=28) were female TRANS, 49% were age TRANS <60. Common comorbidities included diabetes MESHD (22%), hypertension HP hypertension MESHD (27%), cancer MESHD (16%) and cardiovascular disease MESHD (13%). 69% of these (n=38) were RT-PCR confirmed positive for SARS CoV2 infection, 11 had repeated negative nucleic acid testing and an alternate diagnosis. Bayesian inference network, distance metric learning, and ensemble models discriminated between patients with SARS CoV2 infection MESHD and alternate diagnoses with sensitivities SERO of 81.6 to 84.2%, specificities of 58.8 to 70.6%, and accuracies of 61.4 to 71.8%. After integrating imaging and laboratory test statistics with the predictions of the Bayesian inference network, changes in diagnostic uncertainty at each step in the simulated clinical evaluation process were highly sensitive to location, symptom, and diagnostic test choices. Conclusions: Decision support models that incorporate symptoms and available test results can help providers diagnose SARS CoV2 infection MESHD in real world settings.

    How super-spreader cities, highways, hospital bed availability, and dengue fever HP fever MESHD influenced the COVID-19 epidemic in Brazil

    Authors: Miguel A. L. Nicolelis; Rafael L. G. Raimundo; Pedro S. Peixoto; Cecilia Siliansky de Andreazzi; Joelle Dulong; Sarah Carl; Mathieu Lesouhaitier; Murielle Gregoire; Nadine Bescher; Clotilde Verdy; Maelle Latour; Isabelle Bezier; Marie Cornic; Simon Leonard; Jean Feuillard; Vijay Tiwari; Jean Marc Tadie; Michel Cogne; Karin Tarte

    doi:10.1101/2020.09.19.20197749 Date: 2020-09-21 Source: medRxiv

    Although its international airports served as the country's main entry points for SARS-CoV-2, the factors driving the uneven geographic spread of COVID-19 cases and deaths MESHD in Brazil remain largely unknown. Here we show that four major factors likely accounted for the entire dynamics of COVID-19 in Brazil. Mathematical modeling revealed that, initially, the "super-spreading" city of Sao Paulo accounted for roughly 80% of the case spread in the entire country. During the first 3 months of the epidemic, by adding only 16 other spreading cities, we accounted for 98-99% of the cases reported in Brazil at the time. Moreover, 26 of the major Brazilian federal highways accounted for about 30% of SARS-CoV-2's case spread. As cases accumulated rapidly in the Brazilian countryside, the distribution of COVID-19 deaths began to correlate with a third parameter: the geographic distribution of the country's hospital intensive care unit (ICU) beds, which is highly skewed towards state capitals where the epidemic began. That meant that severely ill patients living in the countryside had to be transported to state capitals to access ICU beds where they often died, creating a "boomerang effect" that contributed to the skew of the geographic distribution of COVID-19 deaths. Finally, we discovered that the geographic distribution of dengue fever MESHD fever HP, amounting to more than 3.5 million cases from January 2019 to July 2020, was highly complementary to that of COVID-19. This was confirmed by the identification of significant negative correlations between COVID-19's incidence, infection MESHD growth rate, and mortality to the percentage of people with antibody (IgM SERO) levels for dengue fever HP fever MESHD in each of the country's states. No such correlations were observed when IgM data for chikungunya virus, which is transmitted by the same mosquito vector as dengue, was used. Thus, states in which a large fraction of the population had contracted dengue fever HP fever MESHD in 2019-2020 reported lower COVID-19 cases and deaths, and took longer to reach exponential community transmission TRANS, due to slower SARS-CoV-2 infection MESHD growth rates. This inverse correlation between COVID-19 and dengue fever MESHD fever HP was further observed in a sample of countries around Asia and Latin America, as well as in islands in the Pacific and Indian Oceans. This striking finding raises the intriguing possibility of an immunological cross-reactivity between DENV serotypes and SARS-CoV-2. If proven correct, this hypothesis could mean that dengue infection MESHD or immunization with an efficacious and safe dengue vaccine could produce some level of immunological protection for SARS-CoV-2, before a vaccine for SARS-CoV-2 becomes available.

    Household transmission TRANS in people infected with SARS-CoV-2 (COVID-19) in Metropolitan Lima

    Authors: Yolanda Angulo-Bazán; Gilmer Solis; Joshi Acosta; Fany Cardenas; Ana Jorge; César Cabezas; Maria Jesus Alcaraz; Javier Buesa; Jesus Rodriguez-Diaz; Ron Geller; David Navarro; Maria Gabrani; Michal Rosen-Zvi

    doi:10.1101/2020.09.06.20189456 Date: 2020-09-09 Source: medRxiv

    Objective: Describe the characteristics of SARS-CoV-2 infection MESHD among household members with a confirmed primary case TRANS of COVID-19 in low burden districts in Metropolitan Lima. Materials and Methods: A retrospective, secondary database review study was conducted. The information was collected from an epidemiological surveillance activity in close contacts TRANS (co-inhabitants) in 52 households in Metropolitan Lima with only one member with COVID-19. A reevaluation was carried out in 10 households. Epidemiological and clinical variables were evaluated and its association with the result of the rapid serological test SERO (presence of IgG, IgM or both). Results: Secondary cases TRANS were found in 40 households, which represents an average of 49.9% identification per household. A secondary attack rate TRANS of 53.0% (125 cases) was found among cohabitants, with 77.6% of cases being symptomatic (symptomatic / asymptomatic TRANS ratio: 3.5). The presence of fever HP and / or chills HP was found in 40.0% of people with a positive result, followed by a sore throat, in 39.2%. Ageusia MESHD and anosmia HP anosmia MESHD were present in 22.4% and 20.8% of cases, respectively. A reevaluation in 40 family members TRANS 33.6 +/- 2.7 days after the first evaluation, show the persistence of positive IgM and IgG in the 20 positive cases in the first evaluation. Conclusion: Having a primary case TRANS of COVID-19 in home, the secondary attack rate TRANS of this infection MESHD is 53%; however, in a significant proportion of households evaluated there was no positive case, beyond the primary case TRANS. The epidemiological and clinical characteristics found in this case were in accordance with what has already been reported in other international series.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.